Surgery Dosing Calculator

To calculate dosage, use this unique Dosing Calculator, which makes determination of individualized loading doses of Humate-P fast, easy, and convenient.

Humate-P von Willebrand Disease Dosing Calculator

kg	5	10	15	20	25	30	35	40	45	50	55	60	65	70
lb	11	22	33	44	55	66	77	88	99	110	121	132	143	154
Δ IU/dL*
10	25	50	75	100	125	150	175	200	225	250	275	300	325	350
20	50	100	150	200	250	300	350	400	450	500	550	600	650	700
30	75	150	225	300	375	450	525	600	675	750	825	900	975	1050
40	100	200	300	400	500	600	700	800	900	1000	1100	1200	1300	1400
50	125	250	375	500	625	750	875	1000	1125	1250	1375	1500	1625	1750
60	150	300	450	600	750	900	1050	1200	1350	1500	1650	1800	1950	2100
70	175	350	525	700	875	1050	1225	1400	1575	1750	1925	2100	2275	2450
80	200	400	600	800	1000	1200	1400	1600	1800	2000	2200	2400	2600	2800
90	225	450	675	900	1125	1350	1575	1800	2025	2250	2475	2700	2925	3150
100	250	500	750	1000	1250	1500	1750	2000	2250	2500	2750	3000	3250	3500

kg	75	80	85	90	95	100	105	110	115	120	125	130	135	140
lb	165	176	187	198	209	220	231	242	253	264	275	286	297	308
Δ IU/dL*
10	375	400	425	450	475	500	525	550	575	600	625	650	675	700
20	750	800	850	900	950	1000	1050	1100	1150	1200	1250	1300	1350	1400
30	1125	1200	1275	1350	1425	1500	1575	1650	1725	1800	1875	1950	2025	2100
40	1500	1600	1700	1800	1900	2000	2100	2200	2300	2400	2500	2600	2700	2800
50	1875	2000	2125	2250	2375	2500	2625	2750	2875	3000	3125	3250	3375	3500
60	2250	2400	2550	2700	2850	3000	3150	3300	3450	3600	3750	3900	4050	4200
70	2625	2800	2975	3150	3325	3500	3675	3850	4025	4200	4375	4550	4725	4900
80	3000	3200	3400	3600	3800	4000	4200	4400	4600	4800	5000	5200	5400	5600
90	3375	3600	3825	4050	4275	4500	4725	4950	5175	5400	5625	5850	6075	6300
100	3750	4000	4250	4500	4750	5000	5250	5500	5750	6000	6250	6500	6750	7000

*Δ IU/dL is defined as Target Level (VWF:RC0) - Baseline Level (VWF:RCo)

These calculations are to be used only with Humate-P and are applicable for VWF:RCo loading dose calculations for the prevention of excessive bleeding during and after surgery for all types of VWD.

General Rule: Doses are calculated based on an expected in vivo recovery of 2.0 IU/dL rise in VWF:RCo activity per every IU/kg of VWF:RCo administered.

Please see full dosing recommendations for Humate-P in the full prescribing information.

Important Safety Information

Humate-P is indicated for treatment and prevention of bleeding in adult patients with hemophilia A (classical hemophilia). Humate-P is also indicated in adult and pediatric patients with von Willebrand disease (VWD) for (1) treatment of spontaneous and trauma-induced bleeding episodes, and (2) prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD, and patients with mild and moderate VWD for whom use of desmopressin is known or suspected to be inadequate. Humate-P is not indicated for the prophylaxis of spontaneous bleeding episodes.

Humate-P is contraindicated in individuals with a history of anaphylactic or severe systemic response to antihemophilic factor or von Willebrand factor preparations.

Monitor for intravascular hemolysis and decreasing hematocrit values in patients with A, B, and AB blood groups who are receiving large or frequent doses. Also monitor VWF:RCo and FVIII levels in VWD patients, especially those undergoing surgery.

Thromboembolic events have been reported in VWD patients receiving coagulation factor replacement. Caution should be exercised and antithrombotic measures considered, particularly in patients with known risk factors for thrombosis.

Humate-P is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

In patients receiving Humate-P in clinical studies for treatment of VWD, the most commonly reported adverse reactions observed by >5% of subjects are allergic-anaphylactic reactions, including urticaria (hives), chest tightness, rash, pruritus (itching), and edema (swelling). For patients undergoing surgery, the most common adverse reactions are postoperative wound or injection-site bleeding, and epistaxis (nosebleed).

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

The information provided here is primarily intended for use by physicians and other healthcare professionals in the United States. The CSL Behring product listed may not have been approved in other countries and may not be available everywhere.